One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And ... Sacramento Bee By Boston Scientific Corporation NATICK, Mass., May 15, 2012 -- /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated ... EVOLVE Trial Clinical Results Confirm Data Of The Boston Scientific SYNERGY ... |
